FIELD: biotechnology.
SUBSTANCE: invention relates to an antibody that specifically binds to human HLA-G (hHLA-G), a method for its production, as well as a composition and a kit containing it. Also an isolated nucleic acid encoding the above antibody is disclosed, as well as a vector and a cell containing it is disclosed.
EFFECT: invention is effective for the treatment of a disease or condition in which HLA-G is involved.
20 cl, 10 dwg, 1 tbl, 12 ex
Title | Year | Author | Number |
---|---|---|---|
ANTI-HLA-G ANTIBODIES AND THEIR USE | 2019 |
|
RU2797724C2 |
ANTIBODIES AGAINST XI CLOTTING FACTOR | 2017 |
|
RU2757314C2 |
ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE | 2016 |
|
RU2815681C1 |
HUMANIZED ANTIBODIES AGAINST CD269 (BCMA) | 2015 |
|
RU2749041C2 |
ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
ANTIBODIES AGAINST CTLA4 AND THEIR USE | 2017 |
|
RU2779312C2 |
ANTIBODY AGAINST MUC1 | 2019 |
|
RU2792347C2 |
ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
Authors
Dates
2023-12-26—Published
2019-09-26—Filed